The global vendor-neutral archive market is expected to witness significant growth over the forecast period as it exhibits an inherent advantage over the Picture Archiving and Communication System (PACS) in terms of vendor flexibility and accessibility. A recent development in the PACS market including, a cloud-based PACS solution is expected to spur the market demand over the next few years.
Vendor-neutral archive (VNA) enables the acquisition, management, and storage of images while streamlining communication between multiple vendor PACS. Consolidation of patient information by integrating VNA with Electronic Health Records (EHR) and their subsequent launch is expected to offer avenues for market growth over the forecast period. The vendor-neutral archive market is still in the nascent stage and exhibits considerable growth potential. The industry is characterized by various inter-firm partnerships in order to deliver best-in-class solutions across the healthcare sector, which is also expected to fuel the VNA market demand over the next six years.
Favorable government initiatives encouraging the use of advanced imaging information systems that provide cost benefits are also expected to favorably impact market growth. Surging demand for lifecycle management, disaster recovery, and standard-based storage solutions are also expected to drive market growth. However, lack of awareness, technological complexities, and lack of harmonization in the industry are expected to hamper the VNA market growth. In addition, misinterpretation of VNA concept, data breach incidences, and long VNA lifecycles that impact the buying decision of customers are expected to pose severe challenges to the market.
Key players in vendor-neutral archive market include Siemens Healthcare, Philips Healthcare, Merge Healthcare Inc., McKesson Corporation, GE Healthcare, Fujifilm Corporation, EMC Corporation, Dell Inc., Carestream Health Inc., BridgeHead Software Inc., TeraMedica Inc., and Agfa HealthCare.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
Amongst the majorly used Covid-19 screening options, imaging is preferred by most healthcare professionals as it provides a primary diagnosis in a short time. All the imaging modalities including nuclear imaging have been used exhaustively to study Covid-19 and its effect on different patients in each demography. These are used in theories such as comparison of the vulnerability of pediatric and geriatric patients, and treatment response for several drug combinations. The rising requirement for advanced lung imaging solutions is expected to boost the development studies for lung phantoms. A detailed study on lung deterioration in Covid-19 patients is expected to provide advanced measures for early detection of the disease. The report will account for Covid19 as a key market contributor.